Subtypes


Web

  • http://www.drugs.com/prevnar-13.html
  • Prevnar 13 vaccine is used to prevent infection caused by pneumococcal bacteria.
  • http://www.medicines.org.uk/emc/medicine/1446
  • Primary vaccination: Adults and children of 2 years of age or older- one single dose of 0.5 millilitre by intramuscular or subcutaneous injection.
  • http://www.nps.org.au/medicines/immune-system/vaccines-and-immuni...
  • Pneumovax 23 Solution for injection is a brand of medicine containing the active ingredient pneumococcal vaccine.
  • http://jama.jamanetwork.com/article.aspx?articleid=1355991
  • Vaccination strategies and effectiveness estimates were developed by a Delphi expert panel; indirect (herd immunity) effects resulting from childhood PCV13 vaccination were extrapolated based on observed PCV7 effects.
  • http://www.nhs.uk/Conditions/vaccinations/Pages/pneumococcal-vacc...
  • Find out more about how often to have the pneumococcal vaccine.
  • http://journals.lww.com/pidj/Fulltext/2013/03000/The_13_Valent_Pn...
  • Conclusions: PCV13-serotype IPD incidence declined significantly after PCV13 introduction.Although non-PCV13-serotype IPD also declined significantly, absence of PCV13-serotype IPD in children who received PCV13 suggests a protective vaccine effect....
  • http://www.uptodate.com/contents/pneumococcal-vaccination-in-adults
  • Capsular polysaccharide is the essential component of all pneumococcal vaccines that are currently available.
  • https://en.wikipedia.org/wiki/Pneumococcal_vaccine
  • Pneumococcal vaccines are vaccines against the bacteria Streptococcus pneumoniae.[1] Their use can prevent some cases of pneumonia, meningitis, and sepsis.
  • http://apps.who.int/vaccine_research/diseases/ari/en/index3.html
  • In a case control study in Connecticut, the effectiveness of pneumococcal vaccination with PPV23 in immunocompetent adults was estimated to be 61% against pneumococcal bacteremia, but in immunocompromised patients this figure fell to only 21% [286] . In ...
  • https://www.nlm.nih.gov/medlineplus/ency/article/007605.htm
  • PCV13 is routinely given to children at 2, 4, 6, and 12 to 15 months of age.
  • 1 2 3 4 5 6 7 8 9

    News

    PCV10 Pneumococcal Vaccine Has Big Impact in Kenya, Even Among Unvaccinated Individuals
    Science Daily - Saturday, April 27, 2019
    Pfizer's Prevnar 13 Patent Claims Wiped Out by PTAB
    U.S. Food and Drug Administration - Saturday, March 16, 2019
    Reevaluating Pneumococcal Vaccine Guidance: An Analysis
    Science Daily - Thursday, March 7, 2019
    A recombinant conjugated pneumococcal vaccine that protects against murine infections with a similar efficacy to Prevnar-13
    Nature - Tuesday, November 20, 2018
    Pneumococcal Vaccine Recs Cause Confusion Among Docs
    Physicians Briefing - Saturday, October 27, 2018
    1. 45 million children's lives saved by Hib and pneumococcal vaccines since 2000
    Science Daily - Friday, July 27, 2018
    pcv7_india.jpg
    Global Health - Thursday, July 5, 2018
    Rural/Urban Disparities in Pneumococcal Vaccine Service Delivery Among the Fee-for-Service Medicare Population
    Uknowledge - Friday, February 23, 2018
    Confused About the Pneumococcal Vaccine Schedule? You're Not Alone Confused About the Pneumococcal Vaccine Schedule? You're Not Alone
    Med Worm - Friday, February 16, 2018
    The Ratcheting Price of the Pneumococcal Vaccine: What Gives?
    Medscape - Tuesday, December 5, 2017
    Prevnar 13 Costs Continue Steady Climb (California Healthline)
    Medpage Today - Thursday, November 30, 2017
    The Ratcheting Cost Of The Pneumococcal Vaccine: What Gives?
    Washington Post - Wednesday, November 29, 2017
    Pneumococcal vaccine for adults and older children
    Net Doctor - Friday, November 10, 2017
    Pneumococcal Vaccine for Only Half With Work-Related Asthma
    Physicians Briefing - Thursday, September 28, 2017
    Penicillin Resistance Before and After PCV13 Introduction Penicillin Resistance Before and After PCV13 Introduction
    Med Worm - Monday, August 21, 2017
    Drop in kids, ear infections linked to pneumococcal vaccine
    Orlando Sentinel - Tuesday, August 15, 2017
    Rapid replacement by non-vaccine pneumococcal serotypes may mitigate the impact of the pneumococcal conjugate vaccine on nasopharyngeal bacterial ecology
    Nature - Tuesday, August 15, 2017
    Decline in Kids' Ear Infections Linked to Pneumococcal Vaccine
    Medlineplus - Tuesday, August 8, 2017
    MORE NEWS

    Videos

    February 2014 ACIP Meeting -- Pneumococcal Conjugate Vaccine (PCV) -- Part 1
         
    Introduction, Update on Effectiveness and Impact of PCV13 use among U.S. Children, and GRADE for 3-dose PCV13 schedules. Comments on this video are allowed in accordance with our comment policy: http://www.cdc.gov/SocialMedia/Tools/CommentPolicy.html ...

    Nicaragua pneumococcal vaccine introduction
         
    MANAGUA, Nicaragua, 12 December 2010 - A new vaccine which prevents the most deadly forms of pneumonia - the world's number one killer of children - was introduced today in the routine immunisation programme of a developing country, paving the way to intr...

    Pneumococcal vaccine introduction in Rwanda
         
    As the first developing country to introduce the pneumococcal vaccine in April 2009, Rwanda made a major milestone for disease prevention in the developing world. Find out more about Rwanda's introduction of the pneumococcal vaccine - http://www.gavial...

    Co-contribution of rotavirus and pneumococcal vaccines in reduction of pediatric hospital burden
         
    Ron Dagan, Professor of Pediatrics and Infectious Diseases at the Pediatric Infectious Disease Unit, Soroka University Medical Center, Israel discusses his research that showed how the introduction of both pneumococcal conjugate vaccines and rotavirus vac...

    New Pneumococcal Vaccines Bring Hope to Parents in Yemen
         
    A video from one of our partners, the GAVI Alliance. Pneumonia is the leading killer of children under five in Yemen, with acute respiratory diseases accounting for 20 to 23 per cent of the country's infant deaths.

    This Vaccine Dropped Disease Rates in Kids
         
    http://www.dailyrx.com/pneumococcal-vaccine-reduced-incidence-pneumococcal-disease-children A new pneumococcal vaccine may be key to reducing illness in kids. A new study found that the introduction of a new pneumococcal vaccine may have decreased i...

    UPMC Physician Resources: Pharmacotherapy Pearls
         
  • Design vaccine regimens using the latest pneumococcal vaccine schedule. Identify therapeutic options for venous thromboembolism (VTE) prophylaxis in skilled nursing facility (SNF) residents.

  • UPMC Physician Resources: Pharmacotherapy Pearls
           
    Design vaccine regimens using the latest pneumococcal vaccine schedule.

    Nicaragua pneumococcal vaccine introduction
           
    MANAGUA, Nicaragua, 12 December 2010 - A new vaccine which prevents the most deadly forms of pneumonia - the world's number one killer of children - was introduced today in the routine immunisation programme of a developing country, paving the way to intr...

    1 2 3 4 5 6 7 8 9

    Images

    United States incidence of invasive pneumococcal disease before and after introduction of the 7-valent and 13-valent pneumococcal vaccines.
    Pneumococcal vaccine
    Pneumococcal vaccine
    Abbreviations: PCV7 = 7-valent pneumococcal polysaccharide-protein conjugate vaccine, PCV13 = 13-valent pneumococcal polysaccharide-protein conjugate vaccine,
    Abbreviation: PCV7 = 7-valent pneumococcal polysaccharide-protein conjugate vaccine.
    United States incidence of invasive pneumococcal disease before and after introduction of the 7-valent and 13-valent pneumococcal vaccines.
    en.wikipedia.org
    Pneumococcal vaccine
    drugs.com
    Pneumococcal vaccine
    drugs.com
    Abbreviations: PCV7 = 7-valent pneumococcal polysaccharide-protein conjugate vaccine, PCV13 = 13-valent pneumococcal polysaccharide-protein conjugate vaccine,
    cdc.gov
    Abbreviation: PCV7 = 7-valent pneumococcal polysaccharide-protein conjugate vaccine.
    cdc.gov
    Prevnar 13
    Incidence of invasive pneumococcal disease among adults >65 years of age caused by Streptococcus pneumoniae serotypes included in the 13-valent pneumococcal conjugate vaccine (PCV13) and by non-PCV13 serotype, Centers for Disease Control and Preven
    Thumbnail of Incidence of invasive pneumococcal disease among adults >65 years of age caused by Streptococcus pneumoniae serotypes included in the 13-valent pneumococcal conjugate vaccine (PCV13) and by non-PCV13 serotype, Centers for Disease Contr
    Thumbnail of Incidence of invasive pneumococcal disease among children <5 years of age, caused by Streptococcus pneumoniae serotypes included in the 13-valent pneumococcal conjugate vaccine (PCV13) and by non-PCV13 serotype, Centers for Disease Con
    Pneumovax 23
    Prevnar 13
    drugs.com
    Incidence of invasive pneumococcal disease among adults >65 years of age caused by Streptococcus pneumoniae serotypes included in the 13-valent pneumococcal conjugate vaccine (PCV13) and by non-PCV13 serotype, Centers for Disease Control and Preven
    cdc.gov
    Thumbnail of Incidence of invasive pneumococcal disease among adults >65 years of age caused by Streptococcus pneumoniae serotypes included in the 13-valent pneumococcal conjugate vaccine (PCV13) and by non-PCV13 serotype, Centers for Disease Contr
    cdc.gov
    Thumbnail of Incidence of invasive pneumococcal disease among children <5 years of age, caused by Streptococcus pneumoniae serotypes included in the 13-valent pneumococcal conjugate vaccine (PCV13) and by non-PCV13 serotype, Centers for Disease Con
    cdc.gov
    Pneumovax 23
    drugs.com
    graph of PCV7 serotypes, PCV6(6 serotypes unique to PCV13), and non-vaccine serotypes cases per 100,000 by year, as discussed in Trends in invasive pneumococcal disease section
    Abbreviations: PCV13 = 13-valent pneumococcal conjugate vaccine; IPD = invasive pneumococcal disease; RR = rate ratio; HIV/AIDS = human immunodeficiency virus/acquired immunodeficiency syndrome.
    Thumbnail of Observed (solid lines) and predicted (dashed lines) rates of hospitalization for pneumonia and 95% CIs (shaded area) among children 2 months-2 years of age in 5 cities, Brazil, January 2005-August 2011. The 95% CIs are shown only for the 4 mo
    Thumbnail of Trends in rates of hospitalization for pneumonia (dark gray) and bronchiolitis (light gray) among children 2 months-2 years of age in 5 cities, Brazil, January 2005-August 2011. PCV10, 10-valent pneumococcal vaccine.
    Thumbnail of Trends in rates of hospitalization for pneumonia (black) and for all respiratory causes (light gray) and all causes (dark gray) among children 2 months-2 years of age in 5 cities, Brazil, January 2005-August 2011. PCV10, 10-valent pneumococca
    graph of PCV7 serotypes, PCV6(6 serotypes unique to PCV13), and non-vaccine serotypes cases per 100,000 by year, as discussed in Trends in invasive pneumococcal disease section
    cdc.gov
    Abbreviations: PCV13 = 13-valent pneumococcal conjugate vaccine; IPD = invasive pneumococcal disease; RR = rate ratio; HIV/AIDS = human immunodeficiency virus/acquired immunodeficiency syndrome.
    cdc.gov
    Thumbnail of Observed (solid lines) and predicted (dashed lines) rates of hospitalization for pneumonia and 95% CIs (shaded area) among children 2 months-2 years of age in 5 cities, Brazil, January 2005-August 2011. The 95% CIs are shown only for the 4 mo
    cdc.gov
    Thumbnail of Trends in rates of hospitalization for pneumonia (dark gray) and bronchiolitis (light gray) among children 2 months-2 years of age in 5 cities, Brazil, January 2005-August 2011. PCV10, 10-valent pneumococcal vaccine.
    cdc.gov
    Thumbnail of Trends in rates of hospitalization for pneumonia (black) and for all respiratory causes (light gray) and all causes (dark gray) among children 2 months-2 years of age in 5 cities, Brazil, January 2005-August 2011. PCV10, 10-valent pneumococca
    cdc.gov
    Thumbnail of Monthly coverage for third dose of 10-valent pneumococcal vaccine achieved 11-14 months after vaccination among children <12 months of age in 5 cities in Brazil. Dotted horizontal lines represent 100% vaccination coverage.
    how pneumococcal vaccine works 171x 200 F0010061
    Pneumococcal vaccine
    pneumococcal vaccine why needed 171x 200 M2400778
    Pneumococcal vaccine
    Thumbnail of Monthly coverage for third dose of 10-valent pneumococcal vaccine achieved 11-14 months after vaccination among children <12 months of age in 5 cities in Brazil. Dotted horizontal lines represent 100% vaccination coverage.
    cdc.gov
    how pneumococcal vaccine works 171x 200 F0010061
    nhs.uk
    Pneumococcal vaccine
    healthcentral.com
    pneumococcal vaccine why needed 171x 200 M2400778
    nhs.uk
    Pneumococcal vaccine
    nhs.uk
    Pneumococcal Vaccine
    Pneumococcal vaccine
    Pneumococcal Vaccine
    Pneumococcal vaccine lowers risk of antibiotic resistant infections in children
    Pneumococcal Vaccine in Young Children.
    Pneumococcal Vaccine
    drgreene.com
    Pneumococcal vaccine
    healthcentral.com
    Pneumococcal Vaccine
    drgreene.com
    Pneumococcal vaccine lowers risk of antibiotic resistant infections in children
    insidermedicine.com
    Pneumococcal Vaccine in Young Children.
    uoflphysicians.com
    Pneumococcus (PCV13) Immunization
    Pneumococcal Vaccine 13-Valent Package2.png
    Pneumococcal Vaccine 13-Valent Package1.png
    Percentage of IPD cases caused by serotypes included in pneumococcal vaccines.
    The evidence supporting the use of PCV13 in older adults comes from the Community Acquired Pneumonia Immunization Trial (CAPiTA).4 This randomized, double-blind, placebo-controlled trial analyzed 84,496 patients aged >65 years in the Netherlands.
    Pneumococcus (PCV13) Immunization
    webmd.com
    Pneumococcal Vaccine 13-Valent Package2.png
    wikidoc.org
    Pneumococcal Vaccine 13-Valent Package1.png
    wikidoc.org
    Percentage of IPD cases caused by serotypes included in pneumococcal vaccines.
    merckvaccines.com
    The evidence supporting the use of PCV13 in older adults comes from the Community Acquired Pneumonia Immunization Trial (CAPiTA).4 This randomized, double-blind, placebo-controlled trial analyzed 84,496 patients aged >65 years in the Netherlands.
    uspharmacist.com
    infectiousdisease pos rec 2 kw pneumococcal vaccine polyvalent pneumovax 23 pnuimune cat infectiousdisease cat hospitalacquiredinfections cat immunizations cat vaccinations sz 300x 250 ord 123456789
    FDA approves Prevnar 13 pneumococcal conjugate vaccine for adults 50 and older
    FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine as a single dose for adults
    In April 2015, Bangladesh introduced the pneumococcal vaccine alongside inactivated polio vaccine.
    Learn more from pneumonia and pneumococcal vaccine experts
    infectiousdisease pos rec 2 kw pneumococcal vaccine polyvalent pneumovax 23 pnuimune cat infectiousdisease cat hospitalacquiredinfections cat immunizations cat vaccinations sz 300x 250 ord 123456789
    fpnotebook.com
    FDA approves Prevnar 13 pneumococcal conjugate vaccine for adults 50 and older
    news-medical.net
    FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine as a single dose for adults
    news-medical.net
    In April 2015, Bangladesh introduced the pneumococcal vaccine alongside inactivated polio vaccine.
    gavi.org
    Learn more from pneumonia and pneumococcal vaccine experts
    gavi.org
    Pneumococcal factsheet - GAVI support for pneumococcal vaccines
    Pneumococcal vaccine refugee camp Kenya
    Pneumococcal vaccine launched in Zimbabwe
    21 GAVI-eligible countries have now introduced pneumococcal vaccines
    The rollout of pneumococcal vaccines is underway and could avert over 600,000 deaths from 2016-2020.
    Pneumococcal factsheet - GAVI support for pneumococcal vaccines
    gavi.org
    Pneumococcal vaccine refugee camp Kenya
    gavi.org
    Pneumococcal vaccine launched in Zimbabwe
    gavi.org
    21 GAVI-eligible countries have now introduced pneumococcal vaccines
    gavi.org
    The rollout of pneumococcal vaccines is underway and could avert over 600,000 deaths from 2016-2020.
    gavi.org

    MORE IMAGES